Page last updated: 2024-09-05

deferasirox and Leukemia

deferasirox has been researched along with Leukemia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G1
Agriesti, F; Capitanio, N; De Luca, L; Della Sala, G; Laurenzana, I; Mazzoccoli, C; Musto, P; Pacelli, C; Piccoli, C; Ruggieri, V; Simeon, V; Tataranni, T1
Imanishi, S; Ohsuga, M; Ohyashiki, JH; Ohyashiki, K; Takahashi, R1
Chang, YC; Cheng, HC; Feng, CC; Huang, YT; Lin, CL; Lin, HT; Lo, WJ; Yeh, SP1
Alberti, D; Arruga, F; Bracco, E; Carturan, S; Cilloni, D; Defilippi, I; Greco, E; Maffè, C; Messa, E; Messa, F; Pautasso, M; Pellegrino, RM; Roetto, A; Rosso, V; Rotolo, A; Saglio, G; Zanone, C1
Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E1

Other Studies

6 other study(ies) available for deferasirox and Leukemia

ArticleYear
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
    Oncotarget, 2017, May-30, Volume: 8, Issue:22

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles

2017
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
    Stem cell research & therapy, 2019, 06-13, Volume: 10, Issue:1

    Topics: Blotting, Western; Cell Differentiation; Cell Line; Deferasirox; Gene Expression; Hematopoietic Stem Cells; HL-60 Cells; Humans; Interferons; Leukemia; Mitochondria; Phosphorylation; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Signal Transduction; STAT1 Transcription Factor

2019
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
    Annals of hematology, 2015, Volume: 94, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Deferasirox; HL-60 Cells; Humans; Iron Chelating Agents; Leukemia; Triazoles; U937 Cells

2015
Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Leukemia; Phosphorylation; Reactive Oxygen Species; Triazoles

2017
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
    Haematologica, 2010, Volume: 95, Issue:8

    Topics: Aged; Aged, 80 and over; Apoptosis; Benzoates; Blotting, Western; Deferasirox; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Iron; Iron Chelating Agents; K562 Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; NF-kappa B; Protein Binding; Reactive Oxygen Species; Triazoles

2010
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
    Annals of hematology, 2012, Volume: 91, Issue:5

    Topics: Adolescent; Adult; Benzoates; Deferasirox; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Kidney; Leukemia; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Phlebotomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Triazoles; Young Adult

2012